TWD 179.0
(-1.65%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 857.15 Million TWD | -30.47% |
2022 | 1.23 Billion TWD | 46.87% |
2021 | 839.33 Million TWD | 52.55% |
2020 | 550.18 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 359.08 Million TWD | 1.43% |
2024 Q1 | 354.03 Million TWD | 48.64% |
2023 Q4 | 238.18 Million TWD | -6.66% |
2023 FY | 857.15 Million TWD | -30.47% |
2023 Q3 | 255.18 Million TWD | 20.64% |
2023 Q2 | 211.52 Million TWD | 38.91% |
2023 Q1 | 152.27 Million TWD | -45.32% |
2022 FY | 1.23 Billion TWD | 46.87% |
2022 Q4 | 278.49 Million TWD | 0.0% |
2021 FY | 839.33 Million TWD | 52.55% |
2020 FY | 550.18 Million TWD | 0.0% |
2019 FY | - TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 755.56 Million TWD | -13.446% |
Maxigen Biotech Inc. | 424.09 Million TWD | -102.115% |
SciVision Biotech Inc. | 512.49 Million TWD | -67.252% |
Bionime Corporation | 715.65 Million TWD | -19.773% |
Pegavision Corporation | 3.57 Billion TWD | 75.998% |